Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in Adult HLH
NCT03985423Phase 3Terminated
- Sponsor
- Sobi
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of emapalumab in hemophagocytic lymphohistiocytosis (HLH), sponsored by Sobi. Primary endpoint: Overall Response at 4 weeks. Started Jun 2020; status: terminated.
02
Drugs
emapalumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT03985423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985423.